Principal Investigator
Teshamae Monteith
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20230257
Clinical Trial Summary
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of
Chronic Migraine
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
Other